Inhibition of cathepsin C, a dipeptidyl peptidase that activates many serine proteases, represents an attractive therapeutic strategy for inflammatory diseases with a high neutrophil burden. We recently showed the feasibility of blocking the activation of neutrophil elastase, cathepsin G and proteinase-3 with a single cathepsin C selective inhibitor, in cultured cells. Here we measured the fractional inhibition of cathepsin C that is required for blockade of downstream serine protease processing, in cell-based assays and in vivo. Using a radiolabeled active site probe and U937 cells, a 50% reduction of cathepsin G processing required ~50% of cathepsin C active sites to be occupied by an inhibitor. In EcoM-G cells, inhibition of 50% of neutrophil elastase activity required ~80% occupancy. Both of these serine proteases were fully inhibited at full cathepsin C active site occupancy, whereas granzyme B processing in TALL-104 cells was partially inhibited, despite complete occupancy. In vivo, leukocytes from cathepsin C +/-mice exhibited comparable levels of neutrophil elastase activity to wild-type animals, even though their cathepsin C activity was reduced by half. The chronic administration of a cathepsin C inhibitor to rats, at doses that resulted in the near complete blockade of cathepsin C active sites in bone marrow, caused significant reductions of neutrophil elastase, cathepsin G and proteinase-3 activities. Our results demonstrate that the inhibition of cathepsin C leads to a decrease of activity of multiple serine proteases involved in inflammation, but also suggest that high fractional inhibition is necessary to reach therapeutically significant effects.
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Introduction
Cathepsin C (E.C.3.4.14.1) is a cysteine protease with dipeptidyl aminopeptidase activity that activates several pro-inflammatory serine proteases by removal of an amino-terminal inhibitory dipeptide (McDonald et al., 1969; McGuire et al., 1992; McGuire et al., 1993; Pham and Ley, 1999; Wolters et al., 2001; Sheth et al., 2003; Adkison et al., 2004) .
Cathepsin C mutations in humans are associated with Papillon-Lefèvre syndrome (PLS, MIM#245000), a rare autosomal recessive disorder that is characterized by palmoplantar keratosis and severe pre-pubertal periodontal disease (Toomes et al., 1999; Hart et al., 1999) . In these patients, reductions (>95%) of cathepsin C activity result in complete or near complete loss of the enzymatic activities of the neutral serine proteases cathepsin G (CG), neutrophil elastase (NE) and proteinase-3 (Pr-3; Pham et al., 2004; deHaar et al., 2004) in neutrophils, and granzyme B (gB) in resting NK cells (Meade et al., 2006) . Approximately a fifth of PLS patients exhibit increased susceptibility to infections (Almuneef et al., 2003) , although it is not clear whether this is solely due to lack of neutral serine protease activity. The reduction of serine protease activities was also observed in cathepsin C -/-mice, which showed considerably lowered levels of NE, CG and Pr-3 (Adkison et al., 2002) . In addition, the enzymatic activities of mast cell MOL 45682
observations validate cathepsin C as a interesting target for therapeutic intervention for diseases where serine protease contribute to the pathophysiology, but also impose necessary caution on the possible risks associated with complete cathepsin C inhibition.
Cathepsin C loss-of-function mutations have provided invaluable knowledge of its role in serine protease activation and in their role in inflammation. However, little information is available under circumstances where cathepsin C activity is partially reduced. We recently described potent reversible dipeptide nitrile inhibitors of cathepsin C that blocked the cathepsin C-mediated activation of Pr-3, CG and NE in cells (Méthot et al., 2007) . Here, we investigated the effects of partial cathepsin C inhibition on serine protease activation in cultured cells and in vivo. We used these reversible cathepsin C inhibitors in combination with a radiolabeled active site probe to measure the percentage of cathepsin C blocked by the inhibitors and the functional consequence on serine protease activation. Our results suggest that fractional inhibition requirements for processing of downstream serine protease vary with cell type and target serine protease, but in general, a high degree of cathepsin C inhibition is required for a functional effect.
Cathepsin C fractional inhibition requirements were also investigated in vivo. Peripheral blood leukocytes of cathepsin C +/-mice contained the wild type levels of CG and NE activities, despite a 50% reduction in cathepsin C enzyme activity. These results strongly suggest that greater than 50% of cathepsin C inhibition will be needed for therapeutic success. Indeed, we could show that partial inhibition of CG, Pr-3 and NE was achieved in peripheral blood leukocytes of rats chronically infused with a cathepsin C inhibitor, MOL 45682 directly to the culture media 24 h later. Cells were harvested 48 h after seeding and lysed in lysis buffer B (20 mM Tris-HCl pH 7.5; 100 mM NaCl; 0.2% NP40). Debris was removed by centrifugation at 15,000 x g for 10 min, and supernatants were kept. NE, CG or Pr-3 enzymatic activities were measured as described in Méthot et al., 2007 . Data was plotted using SigmaPlot 9.0 and sigmoidal curve fitting was performed using the Hill 4-parameter equation.
The TALL-104 gB activation cell-based assay was performed as following. TALL-104 cells (ATCC CRL-11386) were propagated in Iscove's Modified Dulbecco Medium (IMDM) supplemented with 20% FBS, 100U/ml each of penicillin, streptomycin and IL-2. The cells were seeded at 3 x 10 6 cells/ml in culture media in the presence of IL-12 (10 ng/ml) and cathepsin C inhibitors. The final DMSO concentration in each well was 0.5%.
The cells were incubated at 37 o C 5% CO 2 in a humidified incubator, harvested by centrifugation 24 h later and washed twice in PBS before lysis with gB activity buffer (20 mM Tris-Cl pH 7.5; 50 mM NaCl; 1 mM EDTA; 5 mM DTT; 0.5% NP-40). Caspase-3 inhibitor (1 µM of M867; Méthot et al., 2004) and cathepsin C inhibitor (1 µM of compound 1; Méthot et al., 2007) were also added to the gB activity buffer to prevent post-lysis activation of gB and caspase-3-mediated cleavage of the synthetic substrate IEPD-AMC (Willoughby et al., 2002; Ewen et al., 2003) . Cell debris was removed by centrifugation, and gB activity determined in the lysate by addition of IEPD-AMC to a final concentration of 200 µM. Release of AMC was measured spectrophotometrically using a Spectramax plate reader (Molecular Devices), with excitation at 355 nm and
This article has not been copyedited and formatted. The final version may differ from this version. pelleted by centrifugation at 400 x g for 5 min washed with PBS containing 1 µM of Ala-4-(I)Phe-DMK and lysed with lysis buffer C (20 mM MES pH 6.0, 50 mM NaCl, 0.5% NP40) for 15 min on ice, before centrifugation at 15,000 x g. Cytosolic extracts were denatured by addition of reducing Laemmli buffer and boiling. Ala-4-( 125 I)Phe-DMKlabeled proteins were resolved on 10-20% SDS-PAGE gels. The gels were fixed, dried and exposed to film for 6-24 h. TALL-104 EOA were also carried out under conditions identical to the serine protease cell-based assay, up to the lysis step. Labeling with Ala-4-( 125 I)Phe-DMK and processing of the cell lysates was performed as described above for EcoM-G cells. U937 EOAs were performed under conditions similar to the pulse-chase assay. The cells were seeded in complete U937 culture media at 2 x 10 6 cells/ml, and In vivo cathepsin C inhibition-The ex vivo cathepsin C EOA was performed using rats This article has not been copyedited and formatted. The final version may differ from this version. reported NE data corresponds to the inhibitable portion of the MeOSuc-Ala-Ala-Pro-Val-AMC-cleaving activity, which typically amounted to 80% of the total. For CG, 100% of Suc-Ala-Ala-Pro-Phe-pNA cleavage was attributed to CG activity. Myeloperoxidase activity was determined in MPO assay buffer containing 50 mM K 2 HPO 4 pH 6.0; 0.05% hexadecylmethylammonium bromide; 0.063 mg/ml o-dianisidine and 0.4 mM H 2 O 2 .
Cytosolic extracts were added to the MPO assay buffer and absorbance at 450 nM was determined kinetically over 5 min. Rates were calculated on the linear portion of the curve.
This article has not been copyedited and formatted. The final version may differ from this version. Western blotting showed that the cathepsin C p23 subunit is present in both undifferentiated and differentiated EcoM-G cells, and that its level of expression is not affected by compound 1 (Fig. 1C ). Taken together, these data demonstrate that Ala-4-( 125 I)Phe-DMK active site probe can be used to estimate the cathepsin C active site occupancy by specific, reversible inhibitors, in live cells.
Cathepsin C active site occupancy and inhibition of downstream serine proteases in cells
Next, we compared the occupancy of cathepsin C active sites present in EcoM-G with the percentage of NE inhibition, over a range of concentrations of cathepsin C inhibitors.
Active site probes such as Ala-4-( 125 I)Phe-DMK have been used to detect cysteine, serine and proteosome proteases in complex tissue extracts or living cells (Liu et al., 1999; Patricelli et al., 2001; Falgueyret et al., 2004; reviewed by Fonović and Bogyo, 2007) . As with cell-surface receptor occupancy studies, a tracer amount of probe should be used to minimize the number of sites occupied by the probe itself and prevent competition with the reversible inhibitor. Labeling times should also be short to limit dissociation of the reversible inhibitor (Farde et al., 1992; Kapur et al., 2001) .
Labeling conditions that
This article has not been copyedited and formatted. The final version may differ from this version. greater labeling intensity of all 4 polypeptides, including the cathepsin C p23 subunit (Fig. 1D) . By densitometry, we estimate that less than 5% of the total cathepsin C active sites are labeled by 15 min of incubation with 0.5 nM of probe, assuming labeling achieved with 50 nM of probe is 100%. These conditions should therefore minimally affect binding equilibrium when a reversible inhibitor is present together with the probe.
To evaluate how a range of cathepsin C active sites occupancy would impact serine protease processing, we compared fractional cathepsin C occupancy and serine protease activity in differentiating EcoM-G. The cells were seeded without β-estradiol to initiate differentiation, in duplicate. Cathepsin C inhibitors were added after 24 h, and incubated for another 24 h. In one set of assays, the cells were harvested and NE activity was measured in lysates. In the duplicate assay, Ala-4-( 125 I)Phe-DMK (0.5 nM) was added to the cultures. Labeling was stopped with an excess of unlabelled Ala-4-(I)Phe-DMK 15 min later. The cells were lysed and cytosolic extracts were resolved by SDS-PAGE. Fig.   3 shows results obtained for a typical EcoM-G cathepsin C enzyme occupancy assay (EOA) with compounds 1 and 2 ( Fig. 3A and B, respectively). Cathepsin C active sites were accessible and labeled by Ala-4-( 125 I)Phe-DMK in the absence of inhibitor (DMSO control, lane 10). As the concentration of compound 1 increased, fewer cathepsin C active sites were available at equilibrium for capture by Ala-4-( 125 I)Phe-DMK, and none were detected at the highest concentration of compound 1 tested. In this particular experiment (one of 3 independent EOA), half of the total available cathepsin C active This article has not been copyedited and formatted. The final version may differ from this version. (Table 1) . Thus, in differentiating EcoM-G cells, an excess of cathepsin C activity must be blocked in order to curb NE processing.
For CG processing inhibition, fractional inhibition requirements must be greater still, since the CG processing IC 50 values were always 3 to 5-fold greater than those for NE processing (Méthot et al., 2007) .
The EOA and serine protease activation dose-response curves were compared in other cell types. U937 cells constitutively synthesize and process CG in a cathepsin Cdependent manner (Méthot et al., 2007) . For all dipeptide nitriles tested, the EOA and CG activation IC 50 values were very similar and overall there was no significant shift between the two assays ( Table 2 ). Based on these results, we conclude that processing of demonstrates that none of the inhibitors affected the total amount of gB protein (Fig. 4B ).
Furthermore, a slight decrease in gB protein mobility was often observed, possibly from the presence of two extra amino acids at the N-terminus that would be expected if cathepsin C activity was blocked. These data indicate that cathepsin C affects gB processing in these cells.
Active site occupancy and gB processing dose-responses were then compared for several cathepsin C inhibitors spanning a wide range of intrinsic potency. At high concentration, compound 1 fully occupied the cathepsin C active sites in TALL-104 (Fig. 4C) .
Surprisingly however, at least 10-fold more inhibitor was required to block 50% of the cathepsin C active sites compared to what was measured in EcoM-G and U937 cells (Tables 1-3) . Despite full occupancy of the active sites, gB processing was inhibited only to a maximum of 80% (Fig. 4D ) and for all compounds tested, the maxima never exceeded 85%. The gB processing dose-response curves were shallow compared to the EOAs, and their IC 50 values were always 3-5 fold greater than the EOA IC 50 value (Table   3 ). These data and other recently published work (see discussion) suggest that although pro-gB can be activated by cathepsin C, at least one other protease is also able to activate the enzyme.
High cathepsin C fractional inhibition is required in vivo for blockade of neutrophil serine proteases
A comparison of IC 50 values for EOA and inhibition of serine protease activity in cells pointed to various cathepsin C fractional inhibition requirements, depending on the cell type and the serine protease. Since granulocytes would be a major site of intervention for pharmaceutical cathepsin C inhibition, we measured NE and myeloperoxidase (MPO) activities in freshly isolated circulating leukocytes from cathepsin C +/+, +/-and -/-mice.
No cathepsin C enzymatic activity was detected in leukocytes from cathepsin C -/-, while about half of the wild type level was measured in cathepsin C +/-cells (Fig. 5A ). In contrast, equal levels of NE activity were measured in leukocytes from cathepsin C +/-and +/+ mice. As expected (Adkison et al., 2002) , cathepsin C -/-leukocytes contained less than 5% of wild type NE activity levels (Fig. 5B) , and MPO activity was equal regardless of the genotype (Fig. 5C ). Based in this, we expect that inhibition of serine protease activities via the pharmacological inhibition of cathepsin C in vivo will require greater than 50% active site occupancy.
This article has not been copyedited and formatted. The final version may differ from this version. , 1980) . We therefore reasoned that cathepsin C inhibition must take place in the bone marrow to be effective.
To determine whether compound 1 can access cathepsin C in the bone marrow, an ex vivo whole cell EOA was performed. Rats (n=3/group) were dosed with compound 1 (10 mg/kg) or vehicle, and marrow from both femurs was recovered 1 h post-dosing. Drug levels were measured in marrow from one femur, while marrow from the other was rapidly suspended in a minimum volume of culture media containing Ala-4-( 125 I)Phe-DMK and incubated for 10 min. Labeling of the 23 kDa cathepsin C subunit was evident in vehicle-treated animals, but significantly (>90%) reduced in compound 1-treated rats (Fig. 5D) . A cathepsin C western blot shows similar levels of 23 kDa subunit in all samples (Fig. 5E ). The concentration of compound 1 in the bone marrow was approximately 1.4 µM. We conclude that compound 1 blocks cathepsin C active sites in vivo in the bone marrow of rats. To test for the effect of compound 1 on serine protease activation in vivo, rats were cannulated in the femoral vein and infused with compound 1 (5 mg/kg/d) or vehicle. NE, CG, Pr-3 and MPO activities were measured in blood leukocytes after 2 weeks of infusion, at which time mature neutrophils that had been This article has not been copyedited and formatted. The final version may differ from this version. Fig   5F) . In contrast, NE, Pr-3 and CG activities were significantly reduced (p<0.05) by 80, 70
and 50%, respectively. The average bone marrow level of compound 1 after 2 weeks' dosing was 3.3 ± 0.5 µM. Thus, the simultaneous reduction of NE, CG and Pr-3 activities in granulocytes is achievable in vivo with a cathepsin C inhibitor in spite of a need for high enzyme occupancy.
Discussion
The inhibition of cathepsin C has the potential to reduce the activity of multiple proinflammatory serine proteases, and is therefore of interest for diseases with a high neutrophil burden, such as COPD and cystic fibrosis. We developed selective, reversible and non-toxic cathepsin C inhibitors, and showed that it is possible to inhibit simultaneously more than 90% of NE, CG and Pr-3 enzyme activities in the neutrophil cell line EcoM-G (Méthot et al., 2007) . In this paper, we investigated further the serine protease inhibition requirements by developing cell-based enzyme occupancy assays (EOA) using the cathepsin C active site probe Ala-4-( 125 I)Phe-DMK. We quantified the percentage of active site that must be blocked in order to affect serine processing in EcoM-G and U937 cells and extended our analysis to a novel cell-based assay that measures gB activation in the CD8+ TALL-104 cell line. In EcoM-G cells, which inducibly express NE, Pr-3 and CG, occupancy of 80% of the cathepsin C active sites reduced NE activity by half, whereas the same 50% inhibition of CG processing in U937
This article has not been copyedited and formatted. The final version may differ from this version. The biology of neutrophil maturation and serine protease activation implies that cathepsin C inhibition must occur in bone marrow to be therapeutically effective. Using an ex vivo EOA, we could show that cathepsin C active sites in the bone marrow of rats treated with compound 1 were almost completely blocked, with a compound 1 concentration of 1.4 µM in the femur marrow. In rats continuously infused for 2 weeks with compound 1, the bone marrow levels reached 3 µM (approximately 130-times the EcoM-G cell cathepsin C EOA IC 50 value), and the net effect on the activities of NE, CG and Pr-3 was an 80%, 50% and 70% reduction, respectively. It is not known presently whether these percentages of inhibition are the maxima achievable, or if further inhibition is possible.
Unfortunately, the chemical properties of compound 1 are not suitable to answer this question as more potent cathepsin C inhibitors would be needed. Compound 1 could not be dosed at higher levels due to its limited solubility in the intravenous vehicle.
Nevertheless, to our knowledge, this is the first in vivo demonstration of the feasibility of This article has not been copyedited and formatted. The final version may differ from this version. inhibiting multiple serine proteases with a single cathepsin C inhibitor. The results also suggest that in vivo efficacy will require a very high fractional inhibition. Interestingly, similarly to what was observed in the EcoM-G cell-based assay (Méthot et al., 2007) , in vivo leukocyte CG activity inhibition was also more difficult than NE and Pr-3 inhibition.
Cathepsin C deficiency in humans causes Papillon-Lefèvre Syndrome (PLS; Toomes et al., 1999; Hart et al., 1999) . Over 41 mutations in the human cathepsin C gene have been documented (Selvaraju et al., 2003 ) and most PLS patients tested exhibit an almost complete (>95%) loss of cathepsin C activity (Hewitt et al., 2003; Pham et al., 2004; deHaar et al., 2004; Nitta et al., 2005) . In two published cases, relatives of PLS showed reduced cathepsin C activity but were asymptomatic (Nitta et al., 2005; Hewitt et al., 2003) . One of these cases is particularly interesting, with a symptom-less sibling of a PLS patient having only 13% of the normal cathepsin C activity (Hewitt et al., 2003) . The latter example supports the notion that very high cathepsin C fractional inhibition will be required for successful therapeutic intervention in humans. This article has not been copyedited and formatted. The final version may differ from this version. The range of potencies against purified cathepsin C varies from 10 nM (cmpd 2) to 1000 nM (cmpd 5) and is shown in Table 1 . This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. 
